

PERSONAL INFORMATION	Giulia Marvaso MD
	📍 University of Milan Department of Oncology and Hemato-Oncology, Faculty of Medicine and Surgery via Festa del Perdono 7, 20122 Milan, Italy
	📍 European Institute of Oncology Radiotherapy Division Via G. Ripamonti 435, 20141 Milan, Italy
	☎ +39 025748932696 📠 +39 3483262369
	✉ giulia.marvaso@unimi.it / giulia.marvaso@ieo.it

WORK EXPERIENCE

February 2024-ongoing	Assistant Professor of Radiation Oncology (RTD-B), University of Milan, Italy
March 2020-March 2022	University researcher (RTD-A) University of Milan, Italy
April 2016-ongoing	Medical doctor, assistant European Institute of Oncology, Radiotherapy Division—Milan Italy
September 2015– March 2016	Medical doctor, research fellow (AIRC) European Institute of Oncology, Radiotherapy Division—Milan Italy

EDUCATION AND TRAINING

February 2024	Assistant Professor of Radiation Oncology (RTD-B), University of Milan, Italy
March 2020 – March 2022	Researcher (A) of Radiation Oncology, University of Milan, Italy
November 2020	National scientific qualification for Associate Professor -sector 06/I1.
June 2015-August 2015	IRCSS Istituto Nazionale dei Tumori of Milan, Italy Observership Pediatric Radiation Oncology Supervisor: Lorenza Gandola MD
May 2015	University "Magna Graecia", Catanzaro (Italy) Specialist in Radiation Oncology (diploma cum laude)
January 2013-May 2014	Massachusetts General Hospital – Harvard Medical School Laboratory of Radiation Oncology Research- Research fellow Supervisor: Prof. Kathryn Held
February 2010	Qualifying examination and certification at the Medical Association of Reggio Calabria Reggio Calabria, Italy
October 2009	University of Messina, Faculty of Medicine and Surgery, Messina, Italy Medical Doctor degree

Personal statement

CLINICAL ACTIVITIES - Dr. Marvaso has extensive expertise in the treatment of genitourinary malignancies, with a particular clinical focus on prostate cancer, kidney cancer, and oligometastatic disease. She leads several prospective protocols for stereotactic body radiotherapy (SBRT), especially in recurrent and oligometastatic settings, and contributes to refining high-precision radiation techniques, including adaptive radiotherapy and image-guided approaches. At IEO, she is an integral member of the Genitourinary Tumor Board, actively involved in personalized treatment planning, integrating clinical, imaging, and molecular data to tailor therapies. Her clinical responsibilities also encompass management of radiorecurrent disease and re-irradiation strategies, with a strong focus on balancing efficacy and toxicity in complex cases.

RESEARCH ACTIVITIES - Dr. Marvaso's research portfolio bridges clinical trials, translational oncology, and implementation science. She is principal and co-investigator in several investigator-initiated and multicenter trials, including the RADIOSA trial (NCT03940235), which explores the synergistic potential of SBRT with short-term androgen deprivation in oligorecurrent prostate cancer. She also contributes to studies evaluating radiogenomic biomarkers,

radiomics-based predictive models, and strategies to integrate molecular diagnostics into standard oncology workflows. Her work has been published in high-impact journals, including The Lancet Oncology and European Urology, and has helped inform multidisciplinary guidelines and consensus statements. In addition to GU cancers, she has published on head and neck cancer, skin toxicity, and patient-reported outcomes.

TEACHING EXPERIENCE - As Assistant Professor at the University of Milan, Dr. Marvaso plays a key role in academic education and residency training. She lectures in radiation oncology for medical students, oncology residents, and PhD candidates, with a focus on evidence-based decision-making, clinical trial interpretation, and translational research. She supervises graduate theses, mentors junior researchers, and contributes to the development of interdisciplinary courses linking radiation oncology with surgical and medical oncology. Her teaching emphasizes not only technical excellence but also the importance of clinical judgment, communication, and collaborative care.

MULTIDISCIPLINARY AND TEAM WORK COMMITMENT - Dr. Marvaso is a strong advocate of multidisciplinary oncology. She collaborates with urologists, medical oncologists, radiologists, pathologists, and molecular biologists to design patient-centered treatment plans and integrated research protocols. She is actively involved in European collaborative networks, including working groups of the European Association of Urology (EAU) and the European Society for Radiotherapy and Oncology (ESTRO), where she contributes to prostate cancer guidelines and consensus initiatives. Her team-oriented approach is reflected in her leadership of cross-functional working groups, participation in tumor boards, and engagement in international task forces aimed at harmonizing clinical practices and promoting innovation in radiation oncology

WORK ACTIVITIES

Awards	12/11/2017 XXVII AIRO 2017 "Il Radioterapista Oncologo tra nuovo imaging e nuovi farmaci" – Best oral presentation Rimini, Italy
	19/12/2017 Award "Quality Day Istituto Europeo di Oncologia 2017" Milano, Italy
	ESTRO Mobility Grant 2019 University of Zurich, project "Treatment outcomes of breast cancer, liver metastases treated with SBRT". 2019
	SIURO 2020 Best poster, 2020, (Pepa M , S.G. Gugliandolo, L.J. Isaksson, G. Marvaso, S. Raimondi, F. Botta, S. Gandini, D. Ciardo, S. Volpe, G. Riva, D.P. Rojas, D. Zerini, P. Pricolo, S. Alessi, G. Petralia, P. Summers, A.F. Mistretta, S. Luzzago, F. Cattani, O. De Cobelli...B.A. Jereczek-Fossa et al. Assessment of mpMRI-based radiomic tools in PCa for cancer aggressiveness prediction, AIRC IG-13218)
	Best article European Urology, 2019 (De Bleser E, Jereczek-Fossa BA, [...] Marvaso G, Goetghebeur E, Ost P. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol. 2019 Jul 19. pii: S0302-2838(19)30533-0. doi: 10.1016/j.eururo.2019.07.009.)
	Award Ricercatori Paladini Italiani della Salute 2ª Edizione April 2024 https://www.rdeditore.it/it/?s=marvaso
Editorial activity	Review board member Frontiers in Oncology (ISSN: 2234-943X) Associate Editor Frontiers in Oncology (ISSN: 2234-943X)
	Ad hoc peer reviewer in numerous journals including: Lancet Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology, Biology, Physics, Tumori Journal, Radiation Oncology, Cancers.
Invited presentations	Teaching lectures and speaker during numerous international and national oncology conferences, etc.
Grants	Collaborator in:
	ERC 2024-ongoing MINIONS (Patient-specific Microstructural and radiobiological model for personalised external beam radiation therapy in localised tumours) Principal Investigator: Prof. Chiara Paganelli (Politecnico, Milano)
	"AIRC20-IG-BARONI", 2021 - 2023/2025 technical framework for combining multi-parametric imaging with advanced modelling in personalized radiotherapy" Principal Investigator: Prof. Guido Baroni (Politecnico, Milano)
	"AIRC18-IG-JERECZEK", 01/01/2018 – 2024 "Radioablation +/- hormone therapy for prostate cancer oligorecurrences (RADIOA trial): potential of imaging and biology" Principal Investigator: Prof Barbara A. Jereczek-Fossa
	"AIRC12-IG-JERECZEK", 01/01/2013 – 31/12/2015 "Short-term high precision radiotherapy for early prostate cancer with concomitant boost on the dominant lesion" Principal Investigator: Prof Barbara A. Jereczek-Fossa
	"AIRC13-IG-ORECCHIA", 01/01/2014 – 2021

"Carbon ions boost followed by pelvic photon radiotherapy for high risk prostate cancer"
Principal Investigator: Prof. Roberto Orecchia

"RICERCA FINALIZZATA RF-2019-12368771" - "Intervention study on Life Style and Microbiota in Prostate Cancer Patients Undergoing Radiotherapy (Microstyle)"
Co-principal investigator with Sara Gandini "

ADDITIONAL INFORMATION


Publications ORCID: <https://orcid.org/0000-0002-5339-8038>
Author of 171 scientific publications (source PUBMED); 3 chapters of oncology/radiotherapy textbooks
H-Index (according to Google Scholar –05.08.2025): 28
H-index (according to Scopus –05.08.2025): 24

20 most relevant publications list:

1. Jereczek-Fossa BA, Mastroleo F, **Marvaso G**. Precision Radiotherapy for Kidney Cancer: A Rising Ally in Multidisciplinary Care. **Eur Urol.** 2025 May 16:S0302-2838(25)00280-5. doi: 10.1016/j.eururo.2025.04.027. Epub ahead of print. PMID: 40382301.
2. **Marvaso G**, Corrao G, Zaffaroni ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOA): a randomised, open-label, phase 2 clinical trial. **Lancet Oncol.** 2025 Mar;26(3):300-311. doi: 10.1016/S1470-2045(24)00730-7. PMID: 40049196.
3. Murthy V, **Marvaso G**, Jereczek-Fossa BA, The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care. **Eur Urol.** 2025 Apr;87(4):379-384. doi: 10.1016/j.eururo.2025.01.003. Epub 2025 Jan 20. PMID: 39837736.
4. **Marvaso G**, Jereczek-Fossa BA, Zaffaroni M, Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. **Lancet Oncol.** 2024 May;25(5):e193-e204. doi: 10.1016/S1470-2045(24)00023-8. PMID: 38697165.
5. Corrao G, **Marvaso G**, Mastroleo F, Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis. **Radiother Oncol.** 2024 Jun;195:110264. doi: 10.1016/j.radonc.2024.110264. Epub 2024 Mar 30. PMID: 38561122.
6. **Marvaso G**, Isaksson LJ, Zaffaroni M Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models. **Eur Radiol.** 2024 Oct;34(10):6241-6253. doi: 10.1007/s00330-024-10699-3. Epub 2024 Mar 20. PMID: 38507053.
7. **Marvaso G**, Corrao G, Repetti I, Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE". **World J Urol.** 2024 Mar 16;42(1):169. doi: 10.1007/s00345-024-04876-8. PMID: 38492078.
8. **Marvaso G**, Volpe S, Pepa M Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. **Eur Urol Open Sci.** 2021 Mar 16;27:19-28. doi: 10.1016/j.euros.2021.02.008. PMID: 34337513; PMCID: PMC8317806.
9. Jereczek-Fossa BA, **Marvaso G**, Zaffaroni M, Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. **Cancer Treat Rev.** 2021 Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. PMID: 33965893.
10. **Marvaso G**, Corrao G, Oneta O, Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? **Clin Transl Oncol.** 2021 Aug;23(8):1717-1726. doi: 10.1007/s12094-021-02574-0. Epub 2021 Mar 9. PMID: 33687659.
11. Gugliandolo SG, Pepa M, Isaksson LJ, **Marvaso G**, MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). **Eur Radiol.** 2021 Feb;31(2):716-728. doi: 10.1007/s00330-020-07105-z. Epub 2020 Aug 27. PMID: 32852590.
12. Isaksson LJ, Pepa M, Zaffaroni M, **Marvaso G**, Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy. **Front Oncol.** 2020 Jun 5;10:790. doi: 10.3389/fonc.2020.00790. PMID: 32582539; PMCID: PMC7289968.
13. Fanetti G, Alterio D, **Marvaso G**, Prognostic significance of neutrophil-to-lymphocyte ratio in HPV status era for oropharyngeal cancer. **Oral Dis.** 2020 Oct;26(7):1384-1392. doi: 10.1111/odi.13366. Epub 2020 May 13. PMID: 32315470.
14. Jereczek-Fossa BA, **Marvaso G**, Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients' selection. **Ann Palliat Med.** 2019 Nov;8(5):786-789. doi: 10.21037/apm.2019.11.02. PMID: 31865738.
15. Alterio D, **Marvaso G**, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA. Modern radiotherapy for head and neck cancer. **Semin Oncol.** 2019 Jun;46(3):233-245. doi: 10.1053/j.seminoncol.2019.07.002. Epub 2019 Jul 26. PMID: 31378376.
16. **Marvaso G**, Ciardo D, Gandini S, Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. **Int J Radiat Oncol Biol Phys.** 2019 Nov 15;105(4):735-744. doi: 10.1016/j.ijrobp.2019.07.027. Epub 2019 Aug 1. PMID: 31377161.
17. Jereczek-Fossa BA, Rojas DP, Zerini D [...] **Marvaso G**, Ciardo D. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). **Br J Radiol.** 2019 Feb;92(1094):20180494. doi: 10.1259/bjr.20180494. Epub 2018 Nov 9. PMID: 30379566; PMCID: PMC6404844.
18. **Marvaso G**, Riva G, Ciardo D, "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach. **Med Oncol.** 2018 May 10;35(6):96. doi: 10.1007/s12032-018-1155-y. PMID: 29748830.
19. Garibaldi C, Jereczek-Fossa BA, **Marvaso G**, Dicuonzo S, Rojas DP, Cattani F, Starzyńska A, Ciardo D, Surgo A, Leonardi MC, Ricotti R. Recent advances in radiation oncology. **Ecancermedicalscience.** 2017 Nov 30;11:785. doi: 10.3332/ecancer.2017.785. PMID: 29225692; PMCID: PMC5718253.
20. Alterio D, **Marvaso G**, Maffini F. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. **Med Oncol.** 2017 Jun;34(6):107. doi: 10.1007/s12032-017-0965-7. Epub 2017 Apr 27. PMID: 28452036.

I authorize the processing of personal data pursuant to Legislative Decree 196/2003

Milan 05.08.2025



Milano 05.08.2025

Care Colleghe,

Cari Colleghi,

è per me un grande onore candidarmi per il ruolo di Coordinatore del gruppo di studio Uro Oncologico della Società Italiana di Radioterapia Oncologica per il biennio 2026-2027. Desidero innanzitutto ringraziare il Prof. Ciro Franzese per il lavoro svolto con dedizione, competenza e visione durante il suo mandato (dove ho partecipato come Segretario del gruppo), che ha rafforzato il ruolo del gruppo AIRO-URO come punto di riferimento nazionale nella radioterapia dei tumori urologici.

In continuità con il percorso già intrapreso, il mio impegno sarà orientato a consolidare e ampliare ulteriormente le attività del gruppo in itinere e nuove, promuovendo un approccio multidisciplinare, basato sull'evidenza scientifica e aperto al confronto costruttivo.

Tra le priorità che intendo sviluppare insieme a tutti voi, vorrei evidenziare i seguenti punti:

- **Consolidamento delle sinergie multidisciplinari**, in particolare con le società scientifiche di Urologia, Oncologia Medica, Medicina Nucleare e Diagnostica per Immagini, per favorire una presa in carico integrata e personalizzata dei pazienti con tumori urologici.
- **Aggiornamento delle raccomandazioni cliniche AIRO-URO**, con la promozione di position paper, documenti di consenso e percorsi diagnostico-terapeutici condivisi, anche in collaborazione con altri gruppi AIRO, alla luce delle più recenti evidenze scientifiche e dei nuovi standard terapeutici.
- **Formazione e coinvolgimento attivo dei giovani radio-oncologi**, attraverso workshop tematici, attività di mentorship e supporto alla partecipazione a progetti di ricerca e produzione scientifica.
- **Sostegno alla ricerca clinica e traslazionale**, anche tramite la promozione di registri nazionali, proposte progettuali multicentriche e sinergie con il network AIRO per la raccolta e l'analisi di dati real-world.
- **Promozione della visibilità e del ruolo della radioterapia nelle patologie urologiche**, attraverso una comunicazione scientifica aggiornata, la partecipazione a eventi nazionali e internazionali, e il dialogo con istituzioni e stakeholder.

Sono convinta che il gruppo URO-oncologico debba continuare a rappresentare un luogo di confronto aperto e inclusivo, in cui ogni contributo, da qualunque sede o esperienza provenga, possa arricchire il nostro percorso comune. La sfida che ci attende è importante: valorizzare l'innovazione tecnologica e l'evoluzione dei modelli di cura, senza mai perdere di vista la centralità del paziente.

Vi ringrazio fin d'ora per la fiducia e la collaborazione che vorrete accordarmi. Sarà mia cura coinvolgere tutti coloro che sono interessati attivamente nelle iniziative del gruppo, con trasparenza ed entusiasmo per le nuove sfide.

Con stima e Cordialità,

Dott.ssa Giulia Marvaso

Candidato a Coordinatore del Gruppo di Studio URO-oncologico
della Società Italiana di Radioterapia Oncologica